Jubilant Life Sciences receives ANDA approval for Rizatriptan Benzoate OD Tablets
Jubilant Life Sciences Ltd has submitted to BSE a copy of Press Release dated October 20, 2015 titled "Jubilant Life Sciences receives ANDA approval for Rizatriptan Benzoate OD Tablets". Jubilant Life Sciences receives ANDA approval for Memantine Hydrochloride Tablets
Jubilant Life Sciences Ltd has submitted to BSE a copy of Press Release dated October 14, 2015 titled "Jubilant Life Sciences receives ANDA approval for Memantine Hydrochloride Tablets". Shareholding Pattern for September 30, 2015
Jubilant Life Sciences Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015. Jubilant Life gets USFDA nod for Indomethacin capsules
Shares of the company were trading at Rs 398.55 apiece, up 0.48%, from the previous close on the BSE Jubilant Life Sciences receives ANDA approval for Indomethacin ER Capsule
Jubilant Life Sciences Ltd has submitted to BSE a copy of Press Release dated October 07, 2015 titled "Jubilant Life Sciences receives ANDA approval for Indomethacin ER Capsule". Exercise of ESOP Options
Jubilant Life Sciences Ltd has informed BSE that 3,600 options under Jubilant Employees Stock Option Plan 2005 (Plan 2005") and 1,23,916 options under JLL Employees Stock Option Plan 2011 (Plan 2011) have been exercised by the option holders.Pursuant to the terms of Plan 2005 and Plan 2011, the Nomination, Remuneration and Compensation Committee of the Company (the Committee) has approved, on i.e. September 29, 2015, transfer of 1,41,916... Jubilant Life gets USFDA nod for anti-migraine tablets
Jubilant Life Sciences today said it has received US health regulator's nod to market its generic zolmitriptan orally disintegrating tablets, an anti-migraine drug, in the American market. Jubilant Life Sciences receives ANDA approval for Zolmitriptan ODT Tablets
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated September 18, 2015, titled "Jubilant Life Sciences receives ANDA approval for Zolmitriptan ODT Tablets". Jubilant signs Term Sheet with Cyclopharm for exclusive license to market Technegas in the United States
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated September 14, 2015 titled "Jubilant signs Term Sheet with Cyclopharm for exclusive license to market Technegas in the United States". Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE